Optibrium, a software developer for drug discovery, has appointed James Halle as its Chief Commercial Officer.
James brings extensive experience in pharma software into the role, and will lead the company to its goal of commercial success.
With more than 20 years experience in leadership, James will be responsible for promoting global sales and marketing, while also managing Optibrium’s commercial team — assisting them in developing product commercialisation strategies.
James joins Optibrium from Cytel, a clinical trials service and software company, where he was the Global Head of Product Growth.
His experience moving from individual software sales to enterprise solutions at Cytel will help drive the growth of Optibrium’s new cloud-based StarDrop, Cerella and Semeta discovery platforms.
Halle has also worked for IQVIA as the Director of Global Technology, Sales, as well as IBM and LexisNexis.
CEO of Optibrium, Dr Matt Segall, said: “We are delighted to welcome James to the team. He has a strong background in sales of innovative software in the pharma market, putting him in a great position to ensure our continued growth and success. I would also like to thank our outgoing CCO, Steve Yemm, for his outstanding contribution to Optibrium’s commercial growth. We wish him every success for his exciting career change as he leaves us to follow his other passion for UK Politics.”
